This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
dlbcl
Diffuse Large B-Cell Lymphoma
Most common aggressive B-cell lymphoma (30% of NHL); GCB subtype driven by t(14;18)/BCL-2 and BCR-PI3K; ABC subtype by MYD88/CD79B/NF-κB. R-CHOP is frontline; CAR-T (axi-cel, liso-cel) and bispecifics (epcoritamab, glofitamab) are approved in relapsed/refractory DLBCL.
Entry Metadata
| Field | Value |
|---|---|
| ID | dlbcl |
| Name | Diffuse Large B-Cell Lymphoma |
| Status | draft |
| Last reviewed | 2026-06-06 |
| Atlas | 01-human |
| Scale | 07-system |
Cross-Atlas Connections
Sources
- Coiffier B, Lepage E, Brière J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235-242. · PubMed 11807147
- Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531-2544. · PubMed 29226797